BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Period	Debt/Equity
2016-12-31	1.50
2017-12-31	0.20
2018-12-31	0.16
2019-12-31	1.14
2020-12-31	0.14
2021-12-31	0.16
2022-12-31	0.24
2023-12-31	0.22
2024-12-31	0.14
2025-12-31	0.09

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BLFS	$25.25	+3.06%	0.54M
3
4
5

BioLife Solutions Inc. (BLFS) Debt to Equity Ratio

Debt to Equity Ratio Data

Get BioLife Solutions Inc. Data in Excel

More BLFS Financial Data